Rejuve Therapeutics is committed to uncovering the key genes that govern the aging and rejuvenation process. Our mission is to halt and reverse aging at its biological roots—the genes to restore vitality, extend the human lifespan, and empower people to live longer, healthier, and more active lives.
We believe that everyone deserves the opportunity to experience 150 years of vibrant, healthy living.
A world where aging is no longer synonymous with decline—where advanced gene therapies allow every person to maintain youthful cellular function, optimal health, and quality of life well into their extended lifespan.
Rejuve Therapeutics, based in Rockville, Maryland, USA, was founded in 2021 to pioneer cutting-edge research and development of solutions aimed at understanding, slowing, and ultimately reversing the aging process.
At Rejuve Therapeutics, we believe that aging is not an inevitable fate. Rather, we see it as a programmed biological process—carefully orchestrated by nature to support the survival of the species as a whole.
Leveraging the power of artificial intelligence and bioinformatics, together with our unique strategies and proprietary rejuvenation screening platform, we are dedicated to identifying the key genes capable of rejuvenating cells in the human body, replicating the natural rejuvenation that occurs during reproduction.
Through our innovative approaches, we strive to develop transformative methods and solutions that halt and reverse aging at its root—extending human lifespan while promoting long-term health, vitality, and active living.
We aim to separate rejuvenation from dedifferentiation during cell reprogramming by blocking dedifferentiation.
Using bioinformatics and AI deep learning, we pinpoint genes highly active in early embryos but inactive in adult cells, and genes highly active in adult cells but inactive in embryos. By adjusting the activity of these genes during reprogramming, we can rejuvenate cells without making them revert to an embryonic state.
We have built a propriety HAEC rejuvenation screening platform (US patent pending) for the high throughput screening of rejuvenation gene cocktails.
We have successfully identified a group of genes that together with reprogramming factors can rejuvenate HAEC while keeping its original phenotype.
Our primary goal is increasing lifespan by addressing fundamental aging processes through targeted genetic interventions.